The Impact of ICH E6 R2

The updated GCP ICH E6 (R2) Addendum is having an overall impact. This webinar explores what this means for you, your company and selected vendors.

Recorded Version Only

(PPT + Recorded Streaming Link)

$299.00
1x Person - Unlimited viewing for 6 Months (For multiple locations contact Customer Care)
rec Recorded Link and Ref. material will be available in My Account Section
Last Recorded Date: Aug-2019

CD or USB Drive Only

(PPT + Recorded Training File)

$399.00
One CD/USB is for usage in one location only.
(For multiple locations contact Customer Care)
CD/USB and Ref. material will be shipped within 15 business days
Customer Care

Fax: +1-650-362-2367

Email: customercare@fdatrainingalert.com

Follow us:
Why Should You Attend:

With the adoption of the ICH E6 R2 addendum, companies are required to have processes and procedures to meet the updated guidelines. Are your company procedures up to date? What if the FDA or EMA came to do an inspection?

With the updating of ICH E6 R2 in the form of an addendum to R1, and acceptance by the FDA in in March 2018, additional processes need to be put into place when conducting Clinical Studies and Operations. The guideline has been updated to encourage implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting. All while continuing to stress the objectives of research and ensure human subject protection and data integrity.

This webinar will review the changes noted in the ICH E6 R2 addendum and point you and your company in the right direction for reviewing and implementing processes to meet those guidelines.

Areas Covered in the Webinar:

Review of ICH E6 R2 Addendum:

  • Why were these changes made?
  • Overall Addendum changes
  • What do these changes mean?
  • Areas that impact clinical operations
Who Will Benefit:
  • Clinical Operations Directors
  • Regulatory Affairs Professionals
  • Clinical Operations personnel
  • Quality Managers
  • GXP
  • Consultants
Instructor Profile:
Pam Dellea Giltner Pam Dellea Giltner

CCEO, PDG Clinical Consulting LLC

Pam Dellea-Giltner is CEO and principal auditor of PDG Clinical Consulting LLC. She has over 30 years of experience in all aspects of Clinical Research Operations. Experience includes Quality Assurance/GCPs, Pre-Inspection Readiness/Audit Reponses, Project Management, Phase I-IV, post marketing and epidemiology studies, Study Management, Vendor/CRO Set up and management.

She has held positions in both pharmaceutical and CRO companies including GCP Auditor, Project Manager, Clinical Research Associate, and Trial Manager.

Currently she is Chairman of the ACRP CCRA Examination Committee and has been a certified CCRA since 2009.

Refund Policy

Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. FDATrainingAlert would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange.

Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time.

If you have any concern about the content of the webinar and not satisfied please contact us at below email or by call mentioning your feedback for resolution of the matter.

We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email customercare@fdatrainingalert.com call +1-888-771-6965 (Toll Free).

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product! Write review

You Recently Viewed